Shanxi Sanjiu Tongda Pharmaceutical Co. Ltd.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation, esomeprazole magnesium enteric-coated capsules (40 mg, provided by Shanxi Tongda Pharmaceutical Co., Ltd.), and the reference formulation, esomeprazole magnesium enteric-coated capsules (NEXIUM®, 40 mg; licensee: AstraZeneca Pharmaceuticals LP), in healthy adult subjects after a meal, and to evaluate the bioequivalence of the two formulations after oral administration. Secondary objective: To evaluate the safety of the test formulation, esomeprazole magnesium enteric-coated capsules, and the reference formulation, esomeprazole magnesium enteric-coated capsules (NEXIUM®), in healthy adult subjects.

Primary objective: To evaluate the bioequivalence of febuxostat tablets (trade name: Feburic®) (40 mg) licensed by Teijin Pharma Limited as the reference formulation and febuxostat tablets (40 mg) licensed by Shanxi Tongda Pharmaceutical Co., Ltd. as the test formulation in a single-center, randomized, open-label, single-dose, two-period, two-sequence, two-crossover clinical trial in postprandial status. Secondary objective: To observe the safety of the test and reference formulations in healthy participants in China.

Primary objective: To evaluate the bioequivalence of febuxostat tablets (trade name: Feburic®) (40 mg) licensed by Teijin Pharma Limited as the reference formulation and febuxostat tablets (40 mg) licensed by Shanxi Tongda Pharmaceutical Co., Ltd. as the test formulation in a single-center, randomized, open-label, single-dose, two-period, two-sequence, two-crossover clinical trial in fasting individuals. Secondary objective: To observe the safety of the test and reference formulations in healthy participants in a Chinese trial.